High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
乐伐替尼和帕博利珠单抗治疗肾癌患者的高缓解率和持久疗效由HLA基因多样性驱动
期刊:Molecular Cancer Research
影响因子:4.1
doi:10.1158/1541-7786.MCR-21-0053
Chung-Han Lee # ,Renzo G DiNatale # ,Diego Chowell # ,Chirag Krishna ,Vladimir Makarov ,Cristina Valero ,Lynda Vuong ,Mark Lee ,Kate Weiss ,Doug Hoen ,Luc Morris ,Ed Reznik ,Samuel Murray ,Ritesh Kotecha ,Martin H Voss ,Maria I Carlo ,Darren Feldman ,Pallavi Sachdev ,Yusuke Adachi ,Yukinori Minoshima ,Junji Matsui ,Yasuhiro Funahashi ,Kenichi Nomoto ,A Ari Hakimi ,Robert J Motzer ,Timothy A Chan